Overview Dividends

(WGS) GeneDx Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US81663L2007

Whole Exome Sequencing, Whole Genome Sequencing, Pediatric Genetic Testing, Rare Disease Diagnostics, AI-Based NGS Platform

WGS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 10.94%
EPS Trend (3Y Correlation): 83.2%

WGS Revenue

Revenue Growth (3Y CAGR): 26.36%
Revenue Trend (3Y Correlation): 92.4%

Description: WGS GeneDx Holdings November 08, 2025

GeneDx Holdings Corp. (NASDAQ: WGS) is a U.S.-based genomics firm that delivers genetic testing services, concentrating on pediatric and rare-disease diagnostics through whole-exome and whole-genome sequencing. The company also offers data-information services and is building an AI-driven platform to automate next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare diseases, hereditary risk, and oncology indications.

As of the most recent quarterly filing (Q2 2024), GeneDx reported revenue of $84 million, representing a year-over-year increase of roughly 12%, driven largely by higher test volumes and expanded payer contracts. The rare-disease diagnostics market is projected to grow at a CAGR of 10-12% through 2030, supported by rising newborn screening mandates and increasing reimbursement for genomic tests. A key sector driver is the accelerating adoption of AI-enabled bioinformatics pipelines, which can reduce per-sample analysis costs by up to 30% and shorten turnaround times-factors that directly affect GeneDx’s operating leverage.

If you’re interested in a deeper quantitative assessment, a quick look at ValueRay’s analytical tools can help you benchmark GeneDx’s valuation metrics against peers and uncover hidden upside.

WGS Stock Overview

Market Cap in USD	3,957m
Sub-Industry	Health Care Equipment
IPO / Inception	2020-11-04

WGS Stock Ratings

Growth Rating	53.7%
Fundamental	56.3%
Dividend Rating	-
Return 12m vs S&P 500	63.0%
Analyst Rating	4.67 of 5

WGS Dividends

Currently no dividends paid

WGS Growth Ratios

Growth Correlation 3m	23.4%
Growth Correlation 12m	63.8%
Growth Correlation 5y	-42.2%
CAGR 5y	61.43%
CAGR/Max DD 3y (Calmar Ratio)	0.64
CAGR/Mean DD 3y (Pain Ratio)	1.35
Sharpe Ratio 12m	-0.20
Alpha	54.76
Beta	2.042
Volatility	99.19%
Current Volume	628.2k
Average Volume 20d	458.5k
Stop Loss	129.9 (-7%)
Signal	1.01

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (2.08m TTM) > 0 and > 6% of Revenue (6% = 24.1m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA 17.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 37.29% (prev 40.66%; Δ -3.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 33.2m > Net Income 2.08m (YES >=105%, WARN >=100%)

Net Debt (-34.4m) to EBITDA (24.3m) ratio: -1.41 <= 3.0 (WARN <= 3.5)

Current Ratio 2.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (28.8m) change vs 12m ago 6.28% (target <= -2.0% for YES)

Gross Margin 69.65% (prev 54.23%; Δ 15.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 89.10% (prev 65.36%; Δ 23.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.45 (EBITDA TTM 24.3m / Interest Expense TTM 2.72m) >= 6 (WARN >= 3)

Altman Z'' -13.95

(A) 0.30 = (Total Current Assets 237.6m - Total Current Liabilities 87.6m) / Total Assets 493.9m

(B) -2.75 = Retained Earnings (Balance) -1.36b / Total Assets 493.9m

warn (B) unusual magnitude: -2.75 — check mapping/units

(D) -6.72 = Book Value of Equity -1.35b / Total Liabilities 201.6m

Total Rating: -13.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.29

1. Piotroski 6.50pt = 1.50

2. FCF Yield 0.40% = 0.20

3. FCF Margin 3.85% = 0.96

4. Debt/Equity 0.21 = 2.48

5. Debt/Ebitda -1.41 = 2.50

6. ROIC - WACC (= -12.04)% = -12.50

7. RoE 0.78% = 0.06

8. Rev. Trend 92.36% = 6.93

9. EPS Trend 83.25% = 4.16

What is the price of WGS shares?

As of November 09, 2025, the stock is trading at USD 139.73 with a total of 628,158 shares traded.
Over the past week, the price has changed by +2.06%, over one month by +15.71%, over three months by +31.88% and over the past year by +85.86%.

Is GeneDx Holdings a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, GeneDx Holdings is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.29 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of WGS is around 108.42 USD . This means that WGS is currently overvalued and has a potential downside of -22.41%.

Is WGS a buy, sell or hold?

GeneDx Holdings has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy WGS.

Strong Buy: 5
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the WGS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	139.6	-0.1%
Analysts Target Price	139.6	-0.1%
ValueRay Target Price	126.2	-9.7%

WGS Fundamental Data Overview November 04, 2025

Market Cap USD = 3.96b (3.96b USD * 1.0 USD.USD)
P/E Trailing = 1244.6364
P/S = 9.8394
P/B = 12.166
Beta = 2.042
Revenue TTM = 402.2m USD
EBIT TTM = 3.94m USD
EBITDA TTM = 24.3m USD
Long Term Debt = 51.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.43m USD (from shortTermDebt, last quarter)
Debt = 61.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -34.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.86b USD (3.96b + Debt 61.6m - CCE 155.1m)
Interest Coverage Ratio = 1.45 (Ebit TTM 3.94m / Interest Expense TTM 2.72m)
FCF Yield = 0.40% (FCF TTM 15.5m / Enterprise Value 3.86b)
FCF Margin = 3.85% (FCF TTM 15.5m / Revenue TTM 402.2m)
Net Margin = 0.52% (Net Income TTM 2.08m / Revenue TTM 402.2m)
Gross Margin = 69.65% ((Revenue TTM 402.2m - Cost of Revenue TTM 122.1m) / Revenue TTM)
Gross Margin QoQ = 72.40% (prev 69.04%)
Tobins Q-Ratio = 7.82 (Enterprise Value 3.86b / Total Assets 493.9m)
Interest Expense / Debt = 0.91% (Interest Expense 562.0k / Debt 61.6m)
Taxrate = -3.34% (negative due to tax credits) (247.0k / -7.39m)
NOPAT = 4.08m (EBIT 3.94m * (1 - -3.34%)) [negative tax rate / tax credits]
Current Ratio = 2.71 (Total Current Assets 237.6m / Total Current Liabilities 87.6m)
Debt / Equity = 0.21 (Debt 61.6m / totalStockholderEquity, last quarter 292.3m)
Debt / EBITDA = -1.41 (Net Debt -34.4m / EBITDA 24.3m)
Debt / FCF = -2.22 (Net Debt -34.4m / FCF TTM 15.5m)
Total Stockholder Equity = 268.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.42% (Net Income 2.08m / Total Assets 493.9m)
RoE = 0.78% (Net Income TTM 2.08m / Total Stockholder Equity 268.0m)
RoCE = 1.23% (EBIT 3.94m / Capital Employed (Equity 268.0m + L.T.Debt 51.9m))
RoIC = 1.31% (NOPAT 4.08m / Invested Capital 311.7m)
WACC = 13.35% (E(3.96b)/V(4.02b) * Re(13.54%) + D(61.6m)/V(4.02b) * Rd(0.91%) * (1-Tc(-0.03)))
Discount Rate = 13.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.29%
[DCF Debug] Terminal Value 50.10% ; FCFE base≈15.5m ; Y1≈10.2m ; Y5≈4.64m
Fair Price DCF = 1.66 (DCF Value 48.0m / Shares Outstanding 28.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 83.25 | EPS CAGR: 10.94% | SUE: 0.39 | # QB: 0
Revenue Correlation: 92.36 | Revenue CAGR: 26.36% | SUE: 1.93 | # QB: 7

Additional Sources for WGS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle